Endo at outperform by RBC

RBC Capital Markets analyst Ken Trbovich rated Endo Pharmaceuticals Holdings Inc. at outperform, above average risk. The analyst offered some takeaway from a call to the company's chief executive officer regarding the Opana launch. Initial weakness and slowness in the prescription cycle are not unusual and the drug should pick up as information flows to sales reps. The Food and Drug Administration has yet to respond to Opana materials submitted in late June, which means the drug is being promoted but is not available. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down 85 cents, or 2.76%, at $30.00. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.